Name: ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock
Brand: ARCUTIS BIOTHERAPEUTICS INC
Rating: 7 (3 reviews)

ARQT Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum

5 days ago - By: The Motley Fool

Why Shares in Arcutis Biotherapeutics Surged Again This Week

5 days ago - By: Zacks Investment Research - Mentions: ADMA EDIT COGT

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

6 days ago - By: Zacks Investment Research - Mentions: GILD MRK ADMA

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

6 days ago - By: Zacks Investment Research - Mentions: PHAR

Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?

6 days ago - By: Benzinga - Mentions: ARWR HSIC HUM LLY ...

10 Health Care Stocks With Whale Alerts In Today's Session

7 days ago - By: Zacks Investment Research - Mentions: NVO VNDA ADMA

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects

7 days ago - By: Zacks Investment Research - Mentions: NVO ADMA VTYX

VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know

8 days ago - By: Zacks Investment Research - Mentions: GSK ADMA ALEC

Alector Stock Plummets 63% in a Month: Here's What You Need to Know

9 days ago - By: Zacks Investment Research - Mentions: BTSG

Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?

9 days ago - By: Zacks Investment Research

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

9 days ago - By: Arcutis Biotherapeutics, Inc.

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

9 days ago - By: Arcutis Biotherapeutics, Inc.

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

12 days ago - By: Zacks Investment Research - Mentions: ANIP ADMA KOD

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

12 days ago - By: Benzinga

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest

13 days ago - By: Zacks Investment Research - Mentions: NVS ANIP ADMA

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

13 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

15 days ago - By: Zacks Investment Research - Mentions: ANIP ADMA EDIT

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

18 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 days ago - By: Zacks Investment Research - Mentions: SNY NVAX ANIP

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised

19 days ago - By: Zacks Investment Research - Mentions: RDY ANIP ESPR

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

19 days ago - By: Zacks Investment Research - Mentions: PBYI ANIP SNDX

PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised

20 days ago - By: Zacks Investment Research - Mentions: ANIP ACAD SNDX

ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

20 days ago - By: Zacks Investment Research - Mentions: TEVA ANIP SNDX

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

21 days ago - By: Zacks Investment Research - Mentions: ANIP NTLA MIRM

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

21 days ago - By: Zacks Investment Research - Mentions: CORT ANIP

Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down

21 days ago - By: Zacks Investment Research

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade

22 days ago - By: Zacks Investment Research - Mentions: TGTX ANIP NTLA

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

22 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

22 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

26 days ago - By: Zacks Investment Research - Mentions: EXAS

Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?

a month ago - By: Zacks Investment Research

What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock

a month ago - By: Zacks Investment Research - Mentions: GRFS

Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?

a month ago - By: Arcutis Biotherapeutics, Inc.

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

a month ago - By: Arcutis Biotherapeutics, Inc.

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

a month ago - By: The Motley Fool

ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock News

ARQT Latest News, Press Relases and Analysis

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum

Why Shares in Arcutis Biotherapeutics Surged Again This Week

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?

10 Health Care Stocks With Whale Alerts In Today's Session

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects

VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know

Alector Stock Plummets 63% in a Month: Here's What You Need to Know

Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised

ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?

What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock

Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Arcutis Q3 2025 Earnings Call Transcript